Literature DB >> 26857693

Symposium Summary: "Breathe In, Breathe Out, Its Easy: What You Need to Know About Developing Inhaled Drugs".

Jeffrey S Tepper1, Philip J Kuehl2, Stuart Cracknell3, Kristen J Nikula4, Luqi Pei5, James D Blanchard6.   

Abstract

Developing inhaled drugs requires knowledge of lung anatomy, cell biology, respiratory physiology, particle physics, and some plumbing. Although dose makes the poison, in the context of an inhaled drug, the "dose" is not easily defined. This lack of clarity around dose poses issues and challenges in the design of inhalation toxicology programs. To better understand dose, the influence of ventilation is discussed as are the perturbations in pulmonary function observed with inhalation exposure that can affect dose. Methods for determining inhaled drug deposition to arrive at an estimate of lung dose are examined. Equally important to understanding dose are the techniques used to deliver aerosols to animals. With a better understanding of dose and inhalation exposure, species-specific histopathologic lesions, both common background and toxicologically significant lesions, are reviewed. Finally, insight into how regulators synthesize and evaluate these complex findings to assess clinical safety risks is presented.
© The Author(s) 2016.

Keywords:  allometry; deposition; dosimetry; inhalation toxicology; lung imaging; lung pathology; orally inhaled products; pharmacokinetics; pulmonary function; respiratory product development; safety evaluation; safety margins

Mesh:

Substances:

Year:  2016        PMID: 26857693     DOI: 10.1177/1091581815624080

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  8 in total

1.  Toxicology Evaluation of Drugs Administered via Uncommon Routes: Intranasal, Intraocular, Intrathecal/Intraspinal, and Intra-Articular.

Authors:  Armaghan Emami; Jeff Tepper; Brian Short; Tony L Yaksh; Alison M Bendele; Thulasi Ramani; Alvaro F Cisternas; Jay H Chang; R Daniel Mellon
Journal:  Int J Toxicol       Date:  2017-12-21       Impact factor: 2.032

2.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

3.  Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer.

Authors:  James Verco; William Johnston; Michael Frost; Michael Baltezor; Philip J Kuehl; Anita Lopez; Andrew Gigliotti; Steven A Belinsky; Ronald Wolff; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-26       Impact factor: 2.849

4.  Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.

Authors:  Mellissa Gomez; Mushtaq Ahmed; Shibali Das; Joseph McCollum; Leah Mellett; Rosemary Swanson; Ananya Gupta; Nicholas B Carrigy; Hui Wang; David Barona; Shital Bachchhav; Alana Gerhardt; Chris Press; Michelle C Archer; Hong Liang; Emilie Seydoux; Ryan M Kramer; Philip J Kuehl; Reinhard Vehring; Shabaana A Khader; Christopher B Fox
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

5.  Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection.

Authors:  Meghan S Vermillion; Eisuke Murakami; Bin Ma; Jared Pitts; Adrian Tomkinson; Davin Rautiola; Darius Babusis; Hammad Irshad; Dustin Seigel; Cynthia Kim; Xiaofeng Zhao; Congrong Niu; Jesse Yang; Andrew Gigliotti; Nani Kadrichu; John P Bilello; Scott Ellis; Roy Bannister; Raju Subramanian; Bill Smith; Richard L Mackman; William A Lee; Philip J Kuehl; Jim Hartke; Tomas Cihlar; Danielle P Porter
Journal:  Sci Transl Med       Date:  2022-02-23       Impact factor: 17.956

6.  A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.

Authors:  Prakash Khadka; Jack Dummer; Philip C Hill; Rajesh Katare; Shyamal C Das
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

7.  5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.

Authors:  Philip J Kuehl; Carmen S Tellez; Marcie J Grimes; Thomas H March; Mathewos Tessema; David A Revelli; Larry M Mallis; Wendy W Dye; Tyler Sniegowski; Aaron Badenoch; Michael Burke; Devon Dubose; David T Vodak; Maria A Picchi; Steven A Belinsky
Journal:  Br J Cancer       Date:  2020-02-27       Impact factor: 9.075

8.  Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.

Authors:  Adam J Plaunt; Sasha J Rose; Jeong Yeon Kang; Kuan-Ju Chen; Daniel LaSala; Ryan P Heckler; Arielle Dorfman; Barrett T Smith; Donald Chun; Veronica Viramontes; Antonio Macaluso; Zhili Li; Yuchen Zhou; Lilly Mark; Jessica Basso; Franziska G Leifer; Michel R Corboz; Richard W Chapman; David Cipolla; Walter R Perkins; Vladimir S Malinin; Donna M Konicek
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.